---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-159189"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:59:49.095547+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences raises $180M in private placement (up to $354M with warrants); CEO replaced

## Summary
- Gross proceeds of $180M upfront; warrants could add $174M if FDA approves cytisinicline for smoking cessation.
- CEO Richard Stewart steps down April 18; remains on board. New CEO Andrew Goldberg appointed.
- Board adds directors Lucian Iancovici and Aaron Royston; Frazier Life Sciences to designate a third.
- Proceeds to fund Phase 3 e-cigarette cessation trial and commercialization of cytisinicline.
- Warrants exercise price $3.51, expire 20 business days after FDA approval announcement.

## SEC filing metadata
- accession: 0001193125-26-159189
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000119312526159189/0001193125-26-159189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000119312526159189/achv-20260415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-159189
- JSON: https://secwatch.observer/filing/0001193125-26-159189.json
- Plain text: https://secwatch.observer/filing/0001193125-26-159189.txt

## Source-grounded claims
- claim_id: 26534280c4a4c975132abca9e3844b2462022ed0
  claim: ACHIEVE LIFE SCIENCES, INC. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $180.0 million (effective 2026-04-15).
  evidence_excerpt: On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000119312526159189/0001193125-26-159189-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.